Mustang Bio

Mustang Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

Mustang Bio, Inc. (“Mustang”) is a clinical-stage bio-pharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang has partnered with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID.

Company Details

Employees
43
Address
377 Plantation St, Worcester,massachusetts 01605,united States
Phone
(781)652-4500
Email
in****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Worcester, Massachusetts
Looking for a particular Mustang Bio employee's phone or email?

Mustang Bio Questions

News

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for GlobeNewswire

Mustang Bio Announces Pricing of $8 Million Public Offering - Yahoo Finance

Mustang Bio Announces Pricing of $8 Million Public Offering Yahoo Finance

Breakthrough Brain Cancer Treatment: FDA Backs Mustang Bio Therapy After 66-Month Complete Response in Trials - Stock Titan

Breakthrough Brain Cancer Treatment: FDA Backs Mustang Bio Therapy After 66-Month Complete Response in Trials Stock Titan

Mustang Bio, Inc. Completes Public Offering, Raising Approximately $8 Million for Cancer Cell Therapy Development - Nasdaq

Mustang Bio, Inc. Completes Public Offering, Raising Approximately $8 Million for Cancer Cell Therapy Development Nasdaq

Mustang Bio Announces Reverse Stock Split - Yahoo Finance

Mustang Bio Announces Reverse Stock Split Yahoo Finance

Mustang Bio Overcomes Delisting Threat: What This Nasdaq Compliance Means for Investors - Stock Titan

Mustang Bio Overcomes Delisting Threat: What This Nasdaq Compliance Means for Investors Stock Titan

Mustang Bio, Inc. Regains Compliance with Nasdaq Listing Requirements Following Recent Public Offering - Nasdaq

Mustang Bio, Inc. Regains Compliance with Nasdaq Listing Requirements Following Recent Public Offering Nasdaq

Mustang Bio’s CAR-T MB-106 Achieves Responses in 9 of 10 Patients With Waldenstrom Macroglobulinemia - CGTLive®

Mustang Bio’s CAR-T MB-106 Achieves Responses in 9 of 10 Patients With Waldenstrom Macroglobulinemia CGTLive®

MB-101 Receives FDA Orphan Drug Designation for Astrocytoma and Glioblastoma - OncLive

MB-101 Receives FDA Orphan Drug Designation for Astrocytoma and Glioblastoma OncLive

Mustang Bio Secures Critical Nasdaq Extension, Faces January 2025 Deadline for $1 Compliance - Stock Titan

Mustang Bio Secures Critical Nasdaq Extension, Faces January 2025 Deadline for $1 Compliance Stock Titan

Mustang Bio Seeks to Bring CD20-Targeted CAR-T MB-106 From Cancer to Autoimmune Disease - CGTLive®

Mustang Bio Seeks to Bring CD20-Targeted CAR-T MB-106 From Cancer to Autoimmune Disease CGTLive®

FDA Grants Orphan Drug Designation to MB-108 for Malignant Glioma - OncLive

FDA Grants Orphan Drug Designation to MB-108 for Malignant Glioma OncLive

Mustang Bio Announces Favorable Efficacy and Safety Data - GlobeNewswire

Mustang Bio Announces Favorable Efficacy and Safety Data GlobeNewswire

Mustang Bio Inc. (MBIO) reports earnings - qz.com

Mustang Bio Inc. (MBIO) reports earnings qz.com

Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy - GlobeNewswire

Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy GlobeNewswire

Worcester biopharmaceutical firm Mustang Bio to lay off 81% of staff - Worcester Business Journal

Worcester biopharmaceutical firm Mustang Bio to lay off 81% of staff Worcester Business Journal

Mustang Bio Stock Surges: Time to Reconsider? - StocksToTrade

Mustang Bio Stock Surges: Time to Reconsider? StocksToTrade

Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment - Pharmaceutical Technology

Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment Pharmaceutical Technology

Mustang Bio Receives FDA Orphan Drug Designation - TipRanks

Mustang Bio Receives FDA Orphan Drug Designation TipRanks

MB-106 Shows Early Promise in BTKi-Refractory Waldenström Macroglobulinemia/LPL - OncLive

MB-106 Shows Early Promise in BTKi-Refractory Waldenström Macroglobulinemia/LPL OncLive

Mustang Bio sells Worcester facility for $11M, to transfer manufacturing operations - Worcester Business Journal

Mustang Bio sells Worcester facility for $11M, to transfer manufacturing operations Worcester Business Journal

Why Is Mustang Bio (MBIO) Stock Up 347% Today? - InvestorPlace

Why Is Mustang Bio (MBIO) Stock Up 347% Today? InvestorPlace

Mustang Bio, City of Hope CAR-T therapy extends survival in phase 1 glioblastoma trial - Fierce Biotech

Mustang Bio, City of Hope CAR-T therapy extends survival in phase 1 glioblastoma trial Fierce Biotech

Dow Dips 1%; Mustang Bio Shares Spike Higher - Benzinga

Dow Dips 1%; Mustang Bio Shares Spike Higher Benzinga

Mustang Bio picks up St. Jude’s ‘bubble boy’ gene therapy - Fierce Biotech

Mustang Bio picks up St. Jude’s ‘bubble boy’ gene therapy Fierce Biotech

MBIO Stock Price and Chart — NASDAQ:MBIO - TradingView

MBIO Stock Price and Chart — NASDAQ:MBIO TradingView

Mustang Bio (MBIO) Stock Price, News & Analysis - MarketBeat

Mustang Bio (MBIO) Stock Price, News & Analysis MarketBeat

Top Mustang Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant